Voters don’t like ‘Big Pharma.’ But they could soon elect a Senate that includes two pharma lobbyists and a CEO

WASHINGTON — In the past year alone, President Trump has bellyached about drug makers charging “rip-off” prices, numerous Democrats have accused the pharmaceutical industry of pure greed, and polls have shown that voters believe lowering the cost of prescription medicines should be among government’s top priorities.

But if Republicans prevail in just two nailbiter races on Tuesday, the Senate’s ranks would suddenly include two former drug industry lobbyists and even a pharma CEO.